Avian influenza primary prevention

Jump to navigation Jump to search

Avian influenza Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Avian influenza from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Avian influenza primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Avian influenza primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Avian influenza primary prevention

CDC on Avian influenza primary prevention

Avian influenza primary prevention in the news

Blogs on Avian influenza primary prevention

Directions to Hospitals Treating Avian influenza

Risk calculators and risk factors for Avian influenza primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Currently, the best way to prevent infection with avian influenza A viruses is to avoid sources of exposure whenever possible. Most human infections with avian influenza A viruses have occurred following direct close or prolonged contact with sick or dead infected poultry. Chemoprophylaxis with influenza antiviral medications can be considered for all exposed persons. Decisions to initiate antiviral chemoprophylaxis should be based on clinical judgment, with consideration given to the type of exposure and to whether the exposed person is at high risk for complications from influenza.

Preventing Exposure

  • The best way to prevent infection with avian influenza A viruses is to avoid sources of exposure. Most human infections with avian influenza A viruses have occurred following direct or close contact with infected poultry.
  • People who work with poultry or who respond to avian influenza outbreaks are advised to follow recommended biosecurity and infection control practices.
  • These include use of appropriate personal protective equipment and careful attention to hand hygiene.
  • They should also be monitored for illness during and after responding to HPAI outbreaks among poultry.
  • Seasonal influenza vaccination will not prevent infection with avian influenza A viruses, but can reduce the risk of co-infection with human and avian influenza A viruses.

Post-exposure Prophylaxis

Exposure to Birds Infected with Avian Influenza

  • People who have had contact with infected birds may be given influenza antiviral drugs preventatively.
  • An exposed person is defined as a person with contact in the past 10 days to infected sick or dead birds, or infected flocks. Infected refers to infection with avian influenza A viruses associated with severe human disease or which have the potential to cause severe human disease.

Monitoring of Exposed Persons

  • Exposed persons should monitor themselves for new illness for 10 days after the last known exposure. The presence of fever and respiratory symptoms (e.g., cough, sore throat, shortness of breath, difficulty breathing) should be assessed daily during this period.
  • Any exposed person who has a new fever or respiratory symptoms should be referred for prompt medical evaluation, antiviral treatment, and testing for avian influenza (A) virus infection.

Post-exposure Chemoprophylaxis of Exposed Persons

  • When used to prevent seasonal influenza, antiviral drugs are 70% to 90% effective. The numbers for avian influenza are not known.
  • Chemoprophylaxis with influenza antiviral medications can be considered for all exposed persons. Decisions to initiate antiviral chemoprophylaxis should be based on clinical judgment, with consideration given to the type of exposure and to whether the exposed person is at high risk for complications from influenza.
  • If antiviral chemoprophylaxis is initiated, treatment dosing for the neuraminidase inhibitors oseltamivir or zanamivir (one dose twice daily) is recommended in these instances instead of the typical antiviral chemoprophylaxis regimen (once daily).
  • If exposure was time-limited and not ongoing, five days of medication (one dose twice daily), from the last known exposure is recommended.
  • Chemoprophylaxis is not routinely recommended for personnel involved in culling non-infected or likely non-infected bird populations as a control measure or personnel involved in handling sick birds or decontaminating affected environments (including animal disposal) who used proper personal protective equipment.

References

Template:WH Template:WS